Limits...
The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder.

Ko YH, Na KS, Kim CE, Kim SH, Jeon YW, Yi JS, Lee MS, Kim SG, Jeong HG, Jung HY - Psychiatry Investig (2014)

Bottom Line: Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit.The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed.BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Korea University College of Medicine, Ansan Hospital, Ansan, Republic of Korea.

ABSTRACT

Objective: Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics.

Methods: A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit.

Results: The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles.

Conclusion: Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period.

No MeSH data available.


Related in: MedlinePlus

Mean change in the scores on BPRS, CGI-S, and GAF in both ITT sample and completers during switching to ziprasidone. *p<0.05, **p<0.01. BPRS: Brief Psychotic Rating Scale, CGI-S: Clinical Global Impression, GAF: global assessment of functioning, ITT: Intent-To-Treat sample.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4225211&req=5

Figure 1: Mean change in the scores on BPRS, CGI-S, and GAF in both ITT sample and completers during switching to ziprasidone. *p<0.05, **p<0.01. BPRS: Brief Psychotic Rating Scale, CGI-S: Clinical Global Impression, GAF: global assessment of functioning, ITT: Intent-To-Treat sample.

Mentions: The mean total scores on the BPRS significantly decreased from baseline (20.3±11.5) to week 12 (17.7±11.5, F=5.96, df=2.11, p=0.003) (Figure 1). The changes in CGI-S scores from 3.5±1.0 to 3.3±1.0 were not statistically significant but did show evidence of a trend (F=2.65, df=1.91, p=0.07). There were no significant changes in the GAF scores. The completers showed significant changes in scores on the BPRS (F=9.87, df=1.93, p<0.001), CGI-S (F=5.20, df=1.74, p=0.01), and GAF (F=12.37, df=1.65, p<0.001).


The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder.

Ko YH, Na KS, Kim CE, Kim SH, Jeon YW, Yi JS, Lee MS, Kim SG, Jeong HG, Jung HY - Psychiatry Investig (2014)

Mean change in the scores on BPRS, CGI-S, and GAF in both ITT sample and completers during switching to ziprasidone. *p<0.05, **p<0.01. BPRS: Brief Psychotic Rating Scale, CGI-S: Clinical Global Impression, GAF: global assessment of functioning, ITT: Intent-To-Treat sample.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4225211&req=5

Figure 1: Mean change in the scores on BPRS, CGI-S, and GAF in both ITT sample and completers during switching to ziprasidone. *p<0.05, **p<0.01. BPRS: Brief Psychotic Rating Scale, CGI-S: Clinical Global Impression, GAF: global assessment of functioning, ITT: Intent-To-Treat sample.
Mentions: The mean total scores on the BPRS significantly decreased from baseline (20.3±11.5) to week 12 (17.7±11.5, F=5.96, df=2.11, p=0.003) (Figure 1). The changes in CGI-S scores from 3.5±1.0 to 3.3±1.0 were not statistically significant but did show evidence of a trend (F=2.65, df=1.91, p=0.07). There were no significant changes in the GAF scores. The completers showed significant changes in scores on the BPRS (F=9.87, df=1.93, p<0.001), CGI-S (F=5.20, df=1.74, p=0.01), and GAF (F=12.37, df=1.65, p<0.001).

Bottom Line: Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit.The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed.BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Korea University College of Medicine, Ansan Hospital, Ansan, Republic of Korea.

ABSTRACT

Objective: Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics.

Methods: A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit.

Results: The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles.

Conclusion: Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period.

No MeSH data available.


Related in: MedlinePlus